Antithrombotic treatment in transcatheter aortic valve implantation: Insights for cerebrovascular and bleeding events

Journal of the American College of Cardiology

Volumn 62, Issue 25, 2013, Pages 2349-2359

  Rodés Cabau, Josep ^a   Dauerman, Harold L ^b   Cohen, Mauricio G ^c   Mehran, Roxana ^d   Small, Eric M ^e   Smyth, Susan S ^f   Costa, Marco A ^g   Mega, Jessica L ^h   O'Donoghue, Michelle L ^h   Ohman, E Magnus ⁱ   Becker, Richard C ⁱ  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f LEXINGTON VA MEDICAL CENTER   (United States)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antiplatelet agents; bleeding; platelets; stroke; transcatheter aortic valve implantation

Indexed keywords

ACETYLSALICYLIC ACID; ANIVAMERSEN; CLOPIDOGREL; HEPARIN; HIRULOG; PEGNIVACOGIN; PROTAMINE; WARFARIN;

ANTICOAGULANT THERAPY; AORTA STENOSIS; AORTA VALVE PROSTHESIS; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; LOADING DRUG DOSE; LOW DRUG DOSE; MORTALITY; OUTCOME ASSESSMENT; PEROPERATIVE CARE; POSTOPERATIVE CARE; PREDICTIVE VALUE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROCEDURAL SITE REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; THROMBOEMBOLISM; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT DURATION; VALVE DELIVERY CATHETER;

EID: 84881530408     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.03.029     Document Type: Review

References (85)

1. A. Aggarwal, D. Dai, J.S. Rumsfeld, L.W. Klein, and M.T. Roe Incidence and predictors of stroke associated with percutaneous coronary intervention Am J Cardiol 104 2009 349 353
2. H.L. Dauerman, S.V. Rao, F.S. Resnic, and R.J. Applegate Bleeding avoidance strategies. Consensus and controversy J Am Coll Cardiol 58 2011 1 10
3. J. Rodés-Cabau Transcatheter aortic valve implantation: current and future approaches Nat Rev Cardiol 9 2012 15 29
4. S.K. Kodali, M.R. Williams, and C.R. Smith Two-year outcomes after transcatheter or surgical aortic-valve replacement N Engl J Med 366 2012 1686 1695
5. J. Rodés-Cabau, J.G. Webb, and A. Cheung Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience J Am Coll Cardiol 55 2010 1080 1090
6. M. Thomas, G. Schymik, and T. Walther Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve Circulation 122 2010 62 69
7. M. Thomas, G. Schymik, and T. Walther One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve Circulation 124 2011 425 433
8. N. Piazza, E. Grube, and U. Gerckens Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) CoreValve ReValving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval EuroIntervention 4 2008 242 249
9. H. Eltchaninoff, A. Prat, and M. Gilard Transcatheter aortic valve implantation: early results of the FRANCE (French Aortic National CoreValve and Edwards) registry Eur Heart J 32 2011 191 197
10. R. Zahn, U. Gerckens, and E. Grube Transcatheter aortic valve implantation: first results from a multi-centre real-world registry Eur Heart J 32 2011 198 204
11. J.M. Bosmans, J. Kefer, and B. De Bruyne Procedural, 30-day and one year outcome following CoreValve or Edwards transcatheter aortic valve implantation: results of the Belgian national registry Interact Cardiovasc Thorac Surg 12 2011 762 767
12. N.E. Moat, P. Ludman, and M.A. De Belder Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) registry J Am Coll Cardiol 58 2011 2130 2138
13. Wendler O. The Multicenter SOURCE XT TAVR registry. Paper presented at: EuroPCR 2012; May 17, 2012; Paris, France.
14. A. Linke, U. Gerckens, and P. Wenaweser Treatment of high risk aortic stenosis patients with transcatheter Medtronic CoreValve implantation: results from the international multicenter ADVANCE study J Am Coll Cardiol 59 2012 e8
15. Meredith IT. Australia-New Zealand CoreValve transcatheter aortic valve study. Paper presented at: Transcatheter Valve Therapies: An Advanced Scientific and Clinical Workshop; June 2-5, 2012; Seattle, Washington.
16. M. Gilard, H. Eltchaninoff, and B. Iung Registry of transcatheter aortic-valve implantation in high-risk patients N Engl J Med 366 2012 1705 1715
17. M.B. Leon, C.R. Smith, and M. Mack Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery N Engl J Med 363 2010 1597 1607
18. C.R. Smith, M.B. Leon, and M.J. Mack Transcatheter versus surgical aortic-valve replacement in high-risk patients N Engl J Med 364 2011 2187 2198
19. J.-B. Masson, J. Kovac, and G. Schuler Transcatheter aortic valve implantation: review of the nature, management, and avoidance of procedural complications J Am Coll Cardiol Intv 2 2009 811 820
20. B.P. Halliday, R. Dworakowski, B. Brickham, O. Wendler, and P. MacCarthy Usefulness of periprocedural bleeding to predict outcome after transcatheter aortic valve implantation Am J Cardiol 109 2012 724 728
21. N.M. Van Mieghem, D. Tchetche, and A. Chieffo Incidence, predictors, and implications of access site complications with transfemoral transcatheter aortic valve implantation Am J Cardiol 110 2012 1361 1367
22. G.P. Ussia, M. Barbanti, and A.S. Petronio Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis Eur Heart J 33 2012 969 976
23. C. Tamburino, D. Capodanno, and A. Ramondo Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis Circulation 123 2011 299 308
24. D.C. Miller, E.H. Blackstone, and M.J. Mack Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial J Thorac Cardiovasc Surg 143 2012 832 843
25. S. Stortecky, S. Windecker, and T. Pilgrim Cerebrovascular accidents complicating transcatheter aortic valve implantation: frequency, timing and impact on outcomes EuroIntervention 8 2012 62 70
26. M.B. Leon, N. Piazza, and E. Nikolsky Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium J Am Coll Cardiol 57 2011 253 269
27. A.P. Kappetein, S.J. Head, and P. Genereux Updated standardized endpoint definitions for transcatheter aortic valve replacement: the VARC-2 consensus document J Am Coll Cardiol 60 2012 1438 1454
28. P. Kahlert, S.C. Knipp, and M. Schlamann Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study Circulation 121 2010 870 878
29. A. Ghanem, A. Müller, and C.P. Nähle Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging J Am Coll Cardiol 55 2010 1427 1432
30. J. Rodés-Cabau, E. Dumont, and R.H. Boone Cerebral embolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches J Am Coll Cardiol 57 2011 18 28
31. T.A. Fairbairn, A.N. Mather, and P. Bijsterveld Diffusion-weighted MRI determined cerebral embolic infarction following transcatheter aortic valve implantation: assessment of predictive risk factors and the relationship to subsequent health status Heart 98 2012 18 23
32. M. Arnold, S. Schulz-Heise, and S. Achenbach Embolic cerebral insults after transapical aortic valve implantation detected by magnetic resonance imaging J Am Coll Cardiol Intv 3 2010 1126 1132
33. B.G. Hynes, and J. Rodés-Cabau Transcatheter aortic valve implantation and cerebrovascular events: the current state of the art Ann N Y Acad Sci 1254 2012 151 163
34. H. Eggebrecht, A. Schmermund, T. Voigtländer, P. Kahlert, R. Erbel, and R.H. Mehta Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients EuroIntervention 8 2012 129 138
35. L. Nombela-Franco, J.G. Webb, and P.P. De Jaegere Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation Circulation 126 2012 3041 3053
36. P. Kahlert, F. Al-Rashid, and P. Dottger Cerebral embolization during transcatheter aortic valve implantation: a transcranial Doppler study Circulation 126 2012 1245 1255
37. D. Messika-Zeitoun, M.-C. Aubry, and D. Detaint Evaluation and clinical implications of aortic valve calcification measured by electron-beam computed tomography Circulation 110 2004 356 362
38. F. Nietlispach, N. Wijesinghe, and R. Gurvitch An embolic deflection device for aortic valve interventions J Am Coll Cardiol Intv 3 2010 1133 1138
39. K. Onsea, P. Agostoni, and M. Samim First-in-man experience with a new embolic deflection device in transcatheter aortic valve interventions EuroIntervention 8 2012 51 56
40. C.K. Naber, A. Ghanem, and A.A. Abizaid First-in-man use of a novel embolic protection device for patients undergoing transcatheter aortic valve implantation EuroIntervention 8 2012 43 50
41. E.L.W. Tay, R. Gurvitch, and N. Wijesinghe A high-risk period for cerebrovascular events exists after transcatheter aortic valve implantation J Am Coll Cardiol Intv 4 2011 1290 1297
42. I.J. Amat-Santos, J. Rodés-Cabau, and M. Urena Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation J Am Coll Cardiol 59 2012 178 188
43. R.-J. Nuis, N.M. Van Mieghem, and C.J. Schultz Frequency and causes of stroke during or after transcatheter aortic valve implantation Am J Cardiol 109 2012 1637 1643
44. J.C.J. Sun, M.J. Davidson, A. Lamy, and J.W. Eikelboom Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends Lancet 374 2009 565 576
45. R.R. Makkar, G.P. Fontana, and H. Jilaihawi Transcatheter aortic-valve replacement for inoperable severe aortic stenosis N Engl J Med 366 2012 1696 1704
46. R.J. Nuis, N. Piazza, and N.M. Van Mieghem In-hospital complications after transcatheter aortic valve implantation revisited according to the Valve Academic Research Consortium definitions Catheter Cardiovasc Interv 78 2011 457 467
47. P. Genereux, J. Webb, and J. Moses Vascular complications after trans-femoral trans-catheter aortic valve replacement (TAVR): insights from the PARTNER trial J Am Coll Cardiol 60 2012 1043 1052
48. R. Gurvitch, S. Toggweiler, and A.B. Willson Outcomes and complications of transcatheter aortic valve replacement using a balloon expandable valve according to the Valve Academic Research Consortium (VARC) guidelines EuroIntervention 7 2011 41 48
49. P. Généreux, S.J. Head, and N.M. Van Mieghem Clinical outcomes after transcatheter aortic valve replacement using Valve Academic Research Consortium definitions: a weighted meta-analysis of 3,519 patients from 16 studies J Am Coll Cardiol 59 2012 2317 2326
50. K. Hayashida, T. Lefèvre, and B. Chevalier Transfemoral aortic valve implantation new criteria to predict vascular complications J Am Coll Cardiol Intv 4 2011 851 858
51. S. Toggweiler, R. Gurvitch, and J. Leipsic Percutaneous aortic valve replacement: vascular outcomes with a fully percutaneous procedure J Am Coll Cardiol 59 2012 113 118
52. D.R. Wong, J. Ye, A. Cheung, J.G. Webb, R.G. Carere, and S.V. Lichtenstein Technical considerations to avoid pitfalls during transapical aortic valve implantation J Thorac Cardiovasc Surg 140 2010 196 202
53. B. Borz, E. Durand, and M. Godin Incidence, predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable Edwards prosthesis Heart 99 2013 860 865
54. T. Pilgrim, S. Stortecky, F. Luterbacher, S. Windecker, and P. Wenaweser Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis J Thromb Thrombolysis 35 2013 456 462
55. P. Genereux, S. Kodali, and M.B. Leon Clinical outcomes using a new crossover balloon occlusion technique for percutaneous closure after transfemoral aortic valve implantation J Am Coll Cardiol Intv 4 2011 861 867
56. R.J. Nuis, J. Rodés-Cabau, and J.M. Sinning Blood transfusion and the risk of acute kidney injury after transcatheter aortic valve implantation Circ Cardiovasc Interv 5 2012 680 688
57. H.L. Dauerman, D. Lessard, J. Yarzebski, J.M. Gore, and R.J. Goldberg Bleeding complications in patients with anemia and acute myocardial infarction Am J Cardiol 96 2005 1379 1383
58. D.R. Holmes Jr., M.J. Mack, and S. Kaul 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement J Am Coll Cardiol 59 2012 1200 1254
59. J. Webb, J. Rodés-Cabau, and S. Fremes Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement Can J Cardiol 28 2012 520 528
60. C.E. Ruiz Optimizing transcatheter aortic valve sizing and minimizing vascular complications J Am Coll Cardiol 59 2012 128 129
61. G.L. Buchanan, A. Chieffo, and M. Montorfano A "modified crossover technique" for vascular access management in high-risk patients undergoing transfemoral transcatheter aortic valve implantation Catheter Cardiovasc Interv 81 2012 579 583
62. K. Hayashida, T. Lefèvre, and B. Chevalier True percutaneous approach for transfemoral aortic valve implantation using the Prostar XL device: impact of learning curve on vascular complications J Am Coll Cardiol Intv 5 2012 207 214
63. K.A. Thompson, K.J. Philip, and E.R. Schwarz Clinical applications of bivalirudin in the cardiac catheterization laboratory J Cardiovasc Pharmacol Ther 16 2011 140 149
64. Z. Sergie, T. Lefèvre, and E. Van Belle Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies J Thromb Thrombolysis 35 2013 483 493
65. S.J. Fearn, A.D. Parry, A.J. Picton, A.J. Mortimer, and C.N. McCollum Should heparin be reversed after carotid endarterectomy? A randomised prospective trial Eur J Vasc Endovasc Surg 13 1997 394 397
66. J.A. Levison, G.R. Faust, and V.J. Halpern Relationship of protamine dosing with postoperative complications of carotid endarterectomy Ann Vasc Surg 13 1999 67 72
67. J. Cosgrave, A. Qasim, A. Latib, T.C. Aranzulla, and A. Colombo Protamine usage following implantation of drug-eluting stents: a word of caution Catheter Cardiovasc Interv 71 2008 913 914
68. T.J. Povsic, J.P. Vavalle, and L.H. Aberle A phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial Eur Heart J 34 2013 2481 2489
69. M. Heras, J.H. Chesebro, and V. Fuster High risk of thromboemboli early after bioprosthetic cardiac valve replacement J Am Coll Cardiol 25 1995 1111 1119
70. R.O. Bonow, B.A. Carabello, and K. Chatterjee 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) J Am Coll Cardiol 52 2008 e1 e142
71. M. Brueck, W. Kramer, and P. Vogt Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors Eur J Cardiothorac Surg 32 2007 108 112
72. J.M. Brennan, F.H. Edwards, and Y. Zhao Early anticoagulation of bioprosthetic aortic valves in older patients: results from The Society of Thoracic Surgeons Adult Cardiac Surgery National Database J Am Coll Cardiol 60 2012 971 977
73. C. Mérie, L. Køber, and P. Skov Olsen Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding JAMA 308 2012 2118 2125
74. F.C. Spencer, F.G. Baumann, E.A. Grossi, A.T. Culliford, and A.C. Galloway Experiences with 1643 porcine prosthetic valves in 1492 patients Ann Surg 203 1986 691 700
75. S. Noble, A. Asgar, R. Cartier, R. Virmani, and R. Bonan Anatomo-pathological analysis after CoreValve ReValving system implantation EuroIntervention 5 2009 78 85
76. G.P. Ussia, M. Scarabelli, and M. Mulè Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation Am J Cardiol 108 2011 1772 1776
77. Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation: the ARTE trial Available at: http://clinicaltrials.gov/ct2/show/ nct01559298?term=nct01559298&rank=1 2012 Accessed May 30, 2012
78. The SPS3 Investigators Effects of clopidogrel added to aspirin in patients with recent lacunar stroke N Engl J Med 367 2012 817 825
79. R.P. Whitlock, and J.W. Eikelboom Prevention of thromboembolic events after bioprosthetic aortic valve replacement: what is the optimal antithrombotic strategy? J Am Coll Cardiol 60 2012 978 980
80. F. Van de Werf, M. Brueckmann, and S.J. Connolly A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients After Heart Valve Replacement (RE-ALIGN) Am Heart J 163 2012 931 937
81. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Drug safety and availability. FDA drug safety communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves. Available at: http://www.fda.gov/drugs/drugsafety/ ucm332912.htm. Accessed February 5, 2013.
82. U. Zeymer, R. Zahn, U. Gerckens, G. Richardt, H.-R. Figulla, and J. Senges Antithrombotic therapy after transfemoral aortic valve implantation (TAVI). Potential hazard of triple-therapy (abstr) Eur Heart J 32 Suppl 2011 900
83. W. Dewilde, and J.T. Berg Design and rationale of the WOEST trial: What Is the Optimal Antiplatelet and Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary Stenting (WOEST) Am Heart J 158 2009 713 718
84. W.J. Dewilde, T. Oirbans, and F.W. Verheugt Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 2013 1107 1115
85. S. Dütting, M. Bender, and B. Nieswandt Platelet GPVI: a target for antithrombotic therapy?! Trends Pharmacol Sci 33 2012 583 590